Conscious living and the economics of war and "terror"
In the two blogs I posted on 9 November 2005 I discussed the terms "conscious" and "conscious living". One of the main things I stressed was the near-impossibility of sustaining a conscious state even if we manage to achieve it, through healing ourselves. Amongst the many kinds of toxicity which make the maintenance of a conscious state so difficult are the messages that daily bombard us in the mass media, especially television. Irrespective of whatever small amounts of truth there may be hidden amongst the mass of half truths, inaccuracies and deliberate distortions to be found in the current "news" about the likelihood of a terror attack or an avian flu pandemic the result is clear. Fear, anxiety, doubt and mass hysteria. These emotions do not help us to remain conscious. There is one antidote to this poison. We need to understand and to be clear about the vast sums of money that are being made by those who claim to have our best interest at heart and who claim to offer us neutral, value-free information ("news").
In 2000, global arms sales amounted to USD$42.1 billion. By 2003 it had dropped to USD$28.5 billion. In 2004 the figure had risen to slightly under USD$37. The 2004 figure was driven by arms deals with so-called "developing" nations, such as India, Saudi Arabia and China (The New York Times, 30 August 2005). The US portion of sales was 33.5% (USD$12.4 billion). The previous year (2003) the corresponding US figure was USD$15.1. Russia was second (in 2004), signing contracts worth USD$6.1 billion, being 16.5% of the total value of contracts (up from the previous year - 2003 - USD$4.4 billion).
In case these figures seem frightening, they represent a tiny fraction of total military spending. The Stockholm International Peace Research Institute (SIPRI), a European think tank funded by the Swedish Government, announced in June of this year that in 2004 global military spending exceeded USD$1 trillion, being USD$1.035 trillion, an increase of 6% on 2003 (expenditure in 2003 was up 6% 0n 2002) (The Age, 8 June 2005). The 2004 expenditure was 6% lower in real terms than it was in 1987-88 which was the peak, according to SIPRI researcher, Elisabeth Skons. The US accounted for 47% of the total, the UK 5% and France also 5%.
It may be difficult to believe, but even these figures, horrendous as they are, understate the actual expenditure, as more and more services (like military training and the provision of logistics in combat zones) are being "outsourced" and not being classified as "military" expenses. According to SIPRI, such "outsourcing" has more than doubled in the past 15 years and is estimated to have amounted to USD$100 million during 2004 (SIPRI researcher, Caroline Holmqvist, cited in The Age, 8 June 2005). This figure (USD$100 million) appears to understate this kind of expenditure by a huge amount, however, as the Washington Post reported a month later that one single company, Halliburton, was paid USD$6.3 billion for such services during the first two years of the "occupation" of Iraq, including USD$3.98 billion between the beginning of May 2004 and the end of May 2005 (Washington Post, 6 July 2005). Even worse figures are reported in the Washington Post, however. Under a new deal which was made public only in July, two months after it took effect, Halliburton will receive USD$4.97 billion during the 12 month period ending in May 2006, to provide logistics support to US troops in Iraq (the services include a continuous supply of food, sanitation, laundry and "other logistical services"). This was revealed by army spokeswoman Linda K Theis (Washington Post, 6 july 2005).
In March 2003 President Bush said that combat in Iraq would cost USD$60 billion. As of March 2005, the cost for military operations alone had hit USD$135.3 billion, according to the Office of management and Budget. But the actual amount spent is far higher, as this figure does not include costs to fund the Coalition Provisional Authority, reconstruction projects or "intelligence operations" (Washington Post, 6 July 2005).
"Halliburton subsidiary, Kellogg Brown and Root has received more money from the US involvement in Iraq than any other contractor", the Washington Post reported in July of this year. The US government is allowed to get away with this in spite of "criticism by administration foes who think Halliburton's high level connections .. most notably its former chief executive, Dick Cheney, who is now vice president .. may have given it undue influence in winning sole-source business" (Washington Post, 6 July 2005). Six weeks later the Washington Post and New york Times both reported that Bunnatine H Greenhouse, a "high level contracting official who has been a vocal critic of the Pentagon's decision to give Halliburton company a multibillion dollar no bid contract for work in Iraq", had been removed from her job as of Saturday 27 august 2005 (Washington post, 29 August 2005).
It is simply inconceivable that, with these sorts of sums at stake, we are going to be told anything other than what is in the interests of those with the power to colonize our consciouness.
Elsewhere I've written in similar terms about the pharmaceutical industry and its hold on government, doctors, scientists and institutes of scientific research such as universities (See, for example, www.consciouslivingseminars.com Journals for May and June 2004). In the August 2004 edition of the Conscious Living Seminars Journal, I wrote the following:
I first read about this (then soon-to-be-released) book (The truth about the drug companies, by Marcia Angell) in the New York Review of Books (Volume 5, Number 12, 15 July, 2004). In that article, written by Marcia Angell, she summarised the main points in the book, points that are not disputed, in spite of their implications. Americans spend $200 billion (AUD$380 billion) each year on prescription drugs, and this figure is increasing at the rate of 12% per year. [This figure – USD$200 billion – “does not include the large amounts spent for drugs administered in hospitals, nursing homes, or doctors’ offices (as is the case for many cancer drugs)”, because these are allocated to costs for these facilities in most analyses.] As a result, “year after year, for over two decades, this industry has been far and away the most profitable in the United States (The New York Review of Books, Volume 51, Number 12, 15 July, 2004). In 2003, for the first time, the pharmaceutical industry came in third, behind “mining, crude oil production” and “commercial banks”.
What this means for individual executives is breathtaking. In 2001, the former chairman and CEO of Bristol-Myers Squibb earned USD$74.9 million, not counting his USD$76.1 million worth of unexercised stock options. The summary of the book states: “Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA and academic medical centres”. The pharmaceutical industry “has the largest lobby in Washington – and more lobbyists than there are elected representatives in Congress” (back cover). “Drug companies promote diseases to match their drugs. Millions of normal Americans have come to believe that they have dubious or exaggerated ailments like ‘generalised anxiety disorder’, ‘erectile dysfunction’, ‘PMDD’ and ‘GERD’”. Pharmaceutical corporations have “enormous influence over what doctors are taught about drugs and what they prescribe”. They “rig clinical trials to make their products look better than they are” (inside front cover).
In the April 2004 Journal, I wrote: A few “facts” might help. In 2002, the ten best-selling drugs in the world brought in more than USD$40 billion (AUD$56 billion) for the manufacturers. These included Zyprexa, an “anti-psychotic” drug made by Eli Lilly (USD$3.7 billion), GlaxoSmithKline’s Paxil (Aropax/Seroxat) (USD$3.2 billion) and Pfizer’s Zoloft (USD$2.7 billion). Pfizer’s return on revenue in 2002 was 28.4%; Eli Lilly’s 24.4%, compared with around 10% or less for other American companies, like General Electric (10.7%) or Exxon Mobil Corp (6.2%) (source: Time, 2 February, 2004/No 4). In 2002, Pfizer reported profits of USD$9.1 billion (AUD$13 billion) on a revenue of USD$32.4 billion (AUD$45 billion), earning a return on revenue of 28%, a rate more than twice that of General Electric (Time, 2 February, 2004, p47).
Time magazine reports that the pharmaceutical industry in the US “maintains more than 600 lobbyists – more than one for every member of Congress”. Pharmaceutical companies spent USD$435 million (AUD$609 million) between 1996 and 2003 in their efforts to influence American decision-makers. Time quotes Pete Stark, a Democrat from California: “These guys are awfully good. I only wish they were on the right side of the issues. They don’t care about curing people. They only care about profits. They are very effective” (Time, 2 February, 2004, p48).
Interestingly, the article in Time magazine from which the above is taken includes the following information: “Actually, pharmaceutical roulette is played every day in the US – with FDA-approved drugs. Each year an estimated 50,000 to 100,000 people die as a result of adverse reactions from FDA-sanctioned pharmaceutical drugs sold in America. In fact, mistakes in administering drugs, often in hospitals, are the fourth- or sixth-leading cause of death in the US, depending on how the cases are counted”. It also discussed a chemical called nefazodone, marketed by Bristol-Myers Squibb as an antidepressant called Serzone, one of the ones added by the FDA to the antidepressants for which it asked that a warning be issued. Throughout the 1990s Bristol-Myers marketed Serzone with ever-growing success. The company’s revenue for the 12 months to 30 September, 2003 was USD$19.9 billion (AUD$28 billion). In an earnings announcement in July, 1996 Bristol-Myers had declared that “sales of central-nervous-system drugs rose, particularly on the strength of STADOL NS, an antimigraine product and Serzone, an antidepressant treatment with a low incidence of side effects”. The following year, medical studies were released claiming “Serzone to be superior to Prozac in increasing sleep efficiency and providing better sleep quality for people suffering from depression”. Yet, “a few years later”, one of Serzone’s “rare but significant side effects” began to leak out, viz liver damage, sometimes requiring a transplant and in extreme cases resulting in death. In 2002 Bristol-Myers announced that it would stop selling the drug in Sweden and the Netherlands and eventually withdrew it from all of Europe and Canada. But not the US!! “The FDA’s only response in the US has been to require a black-box warning on the label, stating in part: ‘Cases of life-threatening hepatic failure have been reported in patients treated with Serzone’” (Time, 2 February, 2004, p46). The New York Times, a mere seven weeks after publication of this article in Time magazine, saw fit to report none of this! Actually, as Time points out, over “the past few years”, the FDA has banned more than half a dozen drugs that it had earlier approved “because the drugs turned out to have an unacceptable degree of fatal side effects” (p46).
How all these things can happen is easy to explain, though difficult to comprehend if one’s humanity is still functioning. The obscene profits mentioned above do not happen by themselves. Many public officials working in regulatory agencies such as the FDA and the CDC (Centres for Disease Control and Prevention) have links with the pharmaceutical industry. Directors of companies manufacturing drugs, medicines and vaccines, such as Eli Lilly and Johnson and Johnson, sit on the boards of newspapers like the New York Times and publishing companies like McGraw Hill. Something like 50% of the “scientific” articles to be found in medical journals are “ghost-written” by employees of the pharmaceutical companies and signed by so-called “scientists” who may not even have seen the raw data. A study reported in the Journal of the American Medical Association (JAMA) in January, 2003 found that one in four biomedical scientists were affiliated with corporations, while two-thirds of universities held equity in start-up companies which sponsored their research. Dr Justin Bekelman, of Yale University School of Medicine, wrote: “This comprehensive review of the literature confirms that financial relationships among industry, scientific investigators and academic institutions are pervasive”. The analysis of 37 scientific papers “found strong and consistent evidence that industry-sponsored research tends to draw conclusions that are supportive of industry”. Dr Bekelman and his colleagues also said that industry-sponsored research “tends to suppress negative studies and publish numerous reports of positive studies about the same drug” (www.abc.net.au/science/news/stories/s768867.htm).
I need to be careful to avoid overkill here. But it surely doesn't take much intelligence to draw conclusions about the "information" we receive from the very sources that stand to benefit from the effect such "information" has on us. If we are to become and then to remain conscious, the first step has to be either to get rid of the TV or to minimise our exposure to the venom it pours into our consciousness. And we need to make sure we view our prepackaged news the same way we view paid advertisements. Most important, we need to protect our children from the material beamed into our living rooms with a full and clear awareness of its power to harm their developing minds. We should view the poison on TV, in the newspapers and in other media the way we view other poisons, like those in the food we eat, the water we drink and the air we breathe.

